Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
暂无分享,去创建一个
Jiang Shou | Rachel Schiff | R. Schiff | C. Osborne | J. Shou | S. Mohsin | C Kent Osborne | Suleiman A Massarweh | Lavina Bharwani | Syed K Mohsin | S. Massarweh | L. Bharwani
[1] Chi-Wai Wong,et al. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Perry,et al. Trastuzumab , 2002, Drugs.
[3] C. Osborne,et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Filardo,et al. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[5] J. Baselga,et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Simak Ali,et al. Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.
[7] N. Weigel,et al. Ligand-independent activation of steroid hormone receptors , 1998, Journal of Molecular Medicine.
[8] S. Hilsenbeck,et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.
[9] G. Figtree,et al. Truncated Estrogen Receptor &agr; 46-kDa Isoform in Human Endothelial Cells: Relationship to Acute Activation of Nitric Oxide Synthase , 2003, Circulation.
[10] R. Schiff,et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] E. Levin. highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors , 2001 .
[12] A. Cato,et al. Rapid Actions of Steroid Receptors in Cellular Signaling Pathways , 2002, Science's STKE.
[13] A. Wellstein,et al. Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway , 2003, Oncogene.
[14] A. Bilancio,et al. Sex steroid hormones act as growth factors , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[15] R. Nicholson,et al. Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer , 2002, Annals of the New York Academy of Sciences.
[16] E. Falkenstein,et al. Nongenomic steroid action: controversies, questions, and answers. , 2003, Physiological reviews.
[17] Chi-Hung Lin,et al. Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer , 2002, International journal of cancer.
[18] Boris Freidlin,et al. Targeting epidermal growth factor receptor—are we missing the mark? , 2003, The Lancet.
[19] J E Paciga,et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.
[20] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[22] E. Levin. Cellular functions of plasma membrane estrogen receptors , 2002, Steroids.
[23] A. Lipton,et al. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. , 2002, Oncology reports.
[24] S. Newman,et al. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer , 2000, Oncogene.
[25] M. van Eickels,et al. Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway* , 2000, The Journal of Biological Chemistry.
[26] R. G. Anderson. The caveolae membrane system. , 1998, Annual review of biochemistry.
[27] R. McPherson,et al. The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.
[28] R. Yarden,et al. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth * , 2001, Journal of cellular biochemistry. Supplement.
[29] Lei Li,et al. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] R. McPherson,et al. Linkage of Rapid Estrogen Action to MAPK Activation by ER-Shc Association and Shc Pathway Activation , 2001 .
[31] E. Levin,et al. Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.
[32] R. Lanz,et al. Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.
[33] Osborne Ck,et al. Tamoxifen in the Treatment of Breast Cancer , 1998 .
[34] G. Figtree,et al. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. , 2000, The Journal of pharmacology and experimental therapeutics.
[35] A. Parfitt,et al. Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids , 2002, Science.
[36] F. Gannon,et al. Identification of a new isoform of the human estrogen receptor‐alpha (hER‐α) that is encoded by distinct transcripts and that is able to repress hER‐α activation function 1 , 2000 .
[37] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[38] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[39] M. Dowsett,et al. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. , 2001, Endocrine-related cancer.
[40] J. Robertson,et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.
[41] M. Russo,et al. Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER α and β subtypes via an Sp1 site , 2003, Oncogene.
[42] C. J. Barnes,et al. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm , 2002, Nature.
[43] J. Liao,et al. Nonnuclear actions of estrogen. , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[44] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.